国际标准期刊号: 2167-065X

临床药理学与生物药剂学

开放获取

我们集团组织了 3000 多个全球系列会议 每年在美国、欧洲和美国举办的活动亚洲得到 1000 多个科学协会的支持 并出版了 700+ 开放获取期刊包含超过50000名知名人士、知名科学家担任编委会成员。

开放获取期刊获得更多读者和引用
700 种期刊 15,000,000 名读者 每份期刊 获得 25,000 多名读者

索引于
  • CAS 来源索引 (CASSI)
  • 哥白尼索引
  • 谷歌学术
  • 夏尔巴·罗密欧
  • Genamics 期刊搜索
  • 参考搜索
  • 哈姆达大学
  • 亚利桑那州EBSCO
  • OCLC-世界猫
  • 普布隆斯
  • 欧洲酒吧
  • ICMJE
分享此页面

抽象的

Clinical Drug Trial Advances: Guaranteeing Safety and Efficacy

Yokoyama Hideshi

Clinical drug trials play a pivotal role in the development of new pharmaceuticals, ensuring that medications are safe and efficacious before they reach the market. Over the years, significant advancements have been made in the design, conduct, and analysis of these trials, enhancing their efficiency and accuracy. This abstract provides an overview of the key developments in clinical drug trials, highlighting the measures taken to enhance safety and efficacy. Advancements in trial design have led to more robust and informative studies. The utilization of adaptive trial designs, Bayesian statistics, and the integration of real-world data have allowed researchers to adapt their protocols in real-time, optimizing patient recruitment, and reducing trial duration. Moreover, the inclusion of patient-reported outcomes and patient-centered trial design has led to a more patient-centric approach, enhancing the relevance of trial results to those who will ultimately benefit from the medications. Advancements in clinical drug trials are ensuring both safety and efficacy in pharmaceutical development. These innovations in trial design, data collection, safety monitoring, and efficacy evaluation are transforming the landscape of drug development, expediting the delivery of life-saving medications to those in need. While challenges and ethical considerations remain, the future of clinical drug trials holds great promise in shaping the future of medicine.

免责声明: 此摘要通过人工智能工具翻译,尚未经过审核或验证。